Treatment of an Adolescent With Chronic Myeloid Leukemia and the T315I Mutation With Ponatinib

被引：21
|
作者：
Nickel, Robert Sheppard [1 ]
Daves, Marla [1 ]
Keller, Frank [1 ]
机构：
[1] Emory Univ, Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Atlanta, GA 30322 USA
来源：
PEDIATRIC BLOOD & CANCER | 2015年 / 62卷 / 11期
关键词：
IMATINIB; GROWTH; CHILDREN;
D O I：
10.1002/pbc.25551
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2050 / 2051
页数：2
相关论文
共 50 条
  • [31] Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34+ cells of patients with de novo chronic myeloid leukemia
    Jurcek, Tomas
    Razga, Filip
    Mazancova, Petra
    Musilova, Milena
    Dvorakova, Dana
    Borsky, Marek
    Zackova, Daniela
    Dobesova, Blanka
    Semerad, Lukas
    Mayer, Jiri
    Racil, Zdenek
    LEUKEMIA & LYMPHOMA, 2014, 55 (08) : 1915 - 1917
  • [32] Ponatinib in the therapy of chronic myeloid leukemia
    Martell, Marc Poch
    Sibai, Hassan
    Deotare, Uday
    Lipton, Jeffrey H.
    EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (10) : 923 - 932
  • [33] New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34+ cells
    Santucci, Maria Alessandra
    Mancini, Manuela
    Corradi, Valentina
    lacobucci, Ilaria
    Martinelli, Giovanni
    Botta, Maurizio
    Schenone, Silvia
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (06) : 876 - 878
  • [34] Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results
    Cortes, Jorge E.
    Sasaki, Koji
    Kim, Dong-Wook
    Hughes, Timothy P.
    Etienne, Gabriel
    Mauro, Michael J.
    Hochhaus, Andreas
    Lang, Fabian
    Heinrich, Michael C.
    Breccia, Massimo
    Deininger, Michael
    Goh, Yeow Tee
    Janssen, Jeroen J. W. M.
    Talpaz, Moshe
    de Soria, Valle Gomez Garcia
    le Coutre, Philipp
    Deangelo, Daniel J.
    Damon, Andrea
    Cacciatore, Silvia
    Polydoros, Fotis
    Agrawal, Nithya
    Rea, Delphine
    LEUKEMIA, 2024, 38 (07) : 1455 - 1468
  • [35] The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia
    Lange, Thoralf
    Ernst, Thomas
    Gruber, Franz X.
    Maier, Jacqueline
    Cross, Michael
    Mueller, Martin C.
    Niederwieser, Dietger
    Hochhaus, Andreas
    Pfirrmann, Markus
    HAEMATOLOGICA, 2013, 98 (05) : 714 - 717
  • [36] SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia
    Wang, Duowei
    Zheng, Yan
    Li, Jiaying
    Wu, Hongxi
    Li, Xianjing
    Tang, Ying
    Liu, Yang
    Li, Jiani
    Sun, Rui
    Zhou, Youli
    Sun, Jihong
    Yang, Yong
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2017, 811 : 117 - 124
  • [37] Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia
    Pavlovsky, Carolina
    Chan, Onyee
    Talati, Chetasi
    Pinilla-Ibarz, Javier
    FUTURE ONCOLOGY, 2019, 15 (03) : 257 - 269
  • [38] Triptolide Inhibits Bcr-Abl Transcription and Induces Apoptosis in STI571-resistant Chronic Myelogenous Leukemia Cells Harboring T315I Mutation
    Shi, Xianping
    Jin, Yanli
    Cheng, Chao
    Zhang, Hui
    Zou, Waiyi
    Zheng, Qin
    Lu, Zhongzheng
    Chen, Qi
    Lai, Yingrong
    Pan, Jingxuan
    CLINICAL CANCER RESEARCH, 2009, 15 (05) : 1686 - 1697
  • [39] Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia
    Huguet, Francoise
    Rea, Delphine
    Cayssials, Emilie
    Etienne, Gabriel
    Nicolini, Franck-Emmanuel
    EXPERT REVIEW OF HEMATOLOGY, 2023,
  • [40] MANAGEMENT OF PONATINIB DOSING IN CHRONIC MYELOID LEUKEMIA PATIENTS
    Sacha, T.
    Szczepanek, E.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2021, 72 (03): : 321 - 327
12345